Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer

Clin Nucl Med. 2018 Dec;43(12):e439-e452. doi: 10.1097/RLU.0000000000002247.

Abstract

There are recent advances, namely, a standardized method for reporting therapy response (Hopkins criteria), a multicenter prospective cohort study with excellent negative predictive value of F-FDG PET/CT for N0 clinical neck, a phase III multicenter randomized controlled study establishing the value of a negative posttherapy F-FDG PET/CT for patient management, a phase II randomized controlled study demonstrating radiation dose reduction strategies for human papilloma virus-related disease, and Food and Drug Administration approval of nivolumab for treatment of recurrent head and neck squamous cell carcinoma.

Publication types

  • Review

MeSH terms

  • Evaluation Studies as Topic
  • Fluorodeoxyglucose F18
  • Head and Neck Neoplasms / diagnostic imaging*
  • Head and Neck Neoplasms / radiotherapy
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Magnetic Resonance Imaging / standards
  • Multimodal Imaging / methods
  • Multimodal Imaging / standards
  • Positron Emission Tomography Computed Tomography / methods*
  • Positron Emission Tomography Computed Tomography / standards
  • Radiopharmaceuticals
  • Randomized Controlled Trials as Topic
  • Squamous Cell Carcinoma of Head and Neck / diagnostic imaging*
  • Squamous Cell Carcinoma of Head and Neck / radiotherapy

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18